The WHO Expert Committee on Drug Dependence (ECDD) is responsible for assessing psychoactive substances for possible control under the international drug control conventions. The ECDD reviews the therapeutic usefulness, the liability for abuse and dependence, and the public health and social harm potential of each substance under review. After the ECDD advises the Director-General of WHO as to whether to schedule or to amend the scheduling status of a substance, the Director-General will, as appropriate, communicate the recommendations to the United Nations Secretary-General. The Secretary-General communicates the advice to the Commission on Narcotic Drugs (CND), as appropriate.

This report presents the recommendations of the thirty-seventh meeting of the WHO Expert Committee on Drug Dependence. The report summarizes the review of nine substances and the ECDD’s recommendations for the scheduling of seven substances. The report also provides updates on ketamine and cannabis, as requested by resolutions of the Commission on Narcotic Drugs. It contains updates on the work of international bodies concerned with controlled substances, as well as summaries of the follow-up discussions on recommendations made at the previous ECDD meeting, and on the discussions on criteria for assessing new psychoactive substances and on terminology.
Table of contents

Abbreviations

Introduction

1. Work of international bodies concerned with controlled substances
   1.1 Update from the International Narcotics Control Board
   1.2 Update from the United Nations Office on Drugs and Crime
   1.3 Update from Management of Substance Abuse Unit, WHO
   1.4 Update from Essential Medicines and Health Products, WHO

2. Criteria for assessing new psychoactive substances

3. Terminology

4. Follow-up on recommendations made by the ECDD at its thirty-sixth meeting
   4.1 Mephedrone
   4.2 Ketamine (INN)
   4.3 AH-7921
   4.4 Gamma-butyrolactone (GBL)
   4.5 1,4-Butanediol (1,4-BD)
   4.6 25B-NBOMe
   4.7 25C-NBOMe
   4.8 25I-NBOMe
   4.9 N-Benzylpiperazine (BZP)
   4.10 JWH-018
   4.11 AM-2201
   4.12 3,4-Methylenedioxypyrovalerone (MDPV)
   4.13 Methyline (BK-MDMA)

5. Critical review of psychoactive substances
   5.1 MT-45
   5.2 Acetylfentanyl
   5.3 α-Pyrrolidinovalerophenone (α-PVP)
   5.4 4-Fluoroamphetamine (4-FA)
   5.5 para-Methyl-4-methylaminorex (4,4′-DMAR)
   5.6 para-Methoxymethylamphetamine (PMMA)
   5.7 Methoxetamine (MXE)

6. Pre-review of psychoactive substances
   6.1 Etizolam (INN)
   6.2 Phenazepam

7. Updates
   7.1 Ketamine (INN)
   7.2 Cannabis and cannabis resin

8. Future agenda items

Acknowledgements

References

ORDER FORM

Please send me ___ copies of WHO Expert Committee on Drug Dependence (37th report) at the price of CHF 14.00/US$ 16.80; In developing countries CHF 9.800/US$ 11.76 (order no. 1100998)

☐ Please add CHF 8.00/US$ 9.60 per copy for postal mail charges in Switzerland
☐ Please add CHF 16.00/US$ 19.20 per copy for courier service charges in Europe
☐ Please add CHF 20.00/US$ 24.00 per copy for courier service charges outside Europe

Name ____________________________
Address ____________________________

☐ Payment enclosed
☐ Please charge to my credit card
   ☐ Visa  ☐ American Express  ☐ Diners Club
   ☐ Eurocard/Access/Mastercard
Card No. ____________________________
Expiry date ____________________________
Date of order ____________________________
Signature ____________________________
Tel/Fax/Email ____________________________

Order online:
www.who.int/bookorders

For multiple copies and bulk orders, please contact WHO Press for a quotation.

WHO, WHO Press, 1211 Geneva 27, Switzerland
Tel +41 22 791 32 64 - Fax +41 22 791 48 57 - Email: bookorders@who.int
Web site: www.who.int/bookorders

WHP:TRS.998